drugset
drugset / Trial / NCT01212341

Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor

NCT01212341 ↗

Phase 1 Completed 18 enrolled Seoul National University Hospital GC Biopharma Corp · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis. These cells were processed based on a novel method for ex vivo activation and expansion using an irradiated and activated autologous feeder cell system. MG4101 has anti-tumor activities against various tumors including malignant lymphomas in vitro as well as in vivo tumor model.

Timeline

Start
2010-09
Primary completion
2012-08
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject MG4101 Cell therapy 1e+06 cells/kg —
Subject MG4101 Cell therapy 3e+06 cells/kg —
Subject MG4101 Cell therapy 1e+07 cells/kg —
Subject MG4101 Cell therapy 3e+07 cells/kg —

Indications

cancer lymphoma